Product Description
Metyrapone is used in the diagnosis of certain problems of the adrenal glands. These glands are located near the kidneys. The adrenal glands produce a steroid chemical called cortisol (hydrocortisone) that helps the body respond to stress or illness. From the results of a metyrapone test, your doctor will be able to tell if your adrenal glands produce the correct amount of cortisol under stress or during illnesses. (Sourced from: https://www.mayoclinic.org/drugs-supplements/metyrapone-oral-route/side-effects/drg-20067784?p=1)
Mechanisms of Action: CYP11B1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Bulgaria | Colombia | Croatia | Czech | Denmark | Estonia | Finland | France | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: Adrenal Insufficiency | Kidney Diseases
Known Adverse Events: Hypotension | Abdominal Pain | Dizziness | Headache | Pain Unspecified
Company: Embera NeuroTherapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Cushing Syndrome|Insulin Resistance|Depressive Disorder|Adenoma|Obesity
Phase 3: Cushing Syndrome|Depressive Disorder|Smoking Cessation|Tobacco Use Disorder
Phase 2: Kidney Diseases|Hypertension, Renal|Cushing Syndrome|Depressive Disorder, Major|Adrenal Insufficiency
Phase 1: Cocaine-Related Disorders|Tobacco Use Disorder|Weight Gain|Obesity|Starvation|Generalized anxiety disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06106295 | P2 |
Recruiting |
Kidney Diseases|Cushing Syndrome|Hypertension, Renal|Adrenal Insufficiency |
2028-01-01 |
|
| 2022-000161-40 | P4 |
Active, not recruiting |
Adenoma |
2025-05-19 |
|
| Gluco-Starve | P1 |
Recruiting |
Starvation |
2024-08-31 |
|
| CEM | N/A |
Recruiting |
Cushing Syndrome|Adrenocortical Hyperfunction |
2024-02-01 |